{"id":"phenylephrine-ketorolac","safety":{"commonSideEffects":[{"rate":null,"effect":"Corneal edema"},{"rate":null,"effect":"Increased intraocular pressure"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Anterior chamber inflammation"}]},"_chembl":{"chemblId":"CHEMBL469","moleculeType":"Small molecule","molecularWeight":"255.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Phenylephrine acts as an alpha-1 adrenergic agonist that constricts blood vessels in the eye, reducing bleeding and improving surgical visibility. Ketorolac is a potent NSAID that inhibits prostaglandin synthesis, further reducing inflammation and bleeding tendency. Together, they provide hemostasis and anti-inflammatory effects during intraocular procedures.","oneSentence":"Phenylephrine-ketorolac is a combination drug that uses a sympathomimetic vasoconstrictor (phenylephrine) and a nonsteroidal anti-inflammatory agent (ketorolac) to reduce bleeding and inflammation during ophthalmic surgery.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:41:06.637Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intraoperative mydriasis and hemostasis during ophthalmic surgery"}]},"trialDetails":[{"nctId":"NCT06681688","phase":"PHASE1, PHASE2","title":"Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC","status":"RECRUITING","sponsor":"Inder Paul Singh, M.D.","startDate":"2024-07-10","conditions":"Cataract","enrollment":94},{"nctId":"NCT05158699","phase":"PHASE3","title":"Effectiveness of Periocular Drug Injection in CATaract Surgery","status":"TERMINATED","sponsor":"Luigi Rondas","startDate":"2021-10-13","conditions":"Macular Edema, Cystoid Macular Edema, Retinal Disease","enrollment":628},{"nctId":"NCT06539637","phase":"EARLY_PHASE1","title":"Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%","status":"RECRUITING","sponsor":"DHS Consulting","startDate":"2023-09-01","conditions":"Cataract","enrollment":20},{"nctId":"NCT03864133","phase":"PHASE4","title":"No Drop Post-Op Cataract Surgery","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-07-08","conditions":"Cataract","enrollment":94},{"nctId":"NCT04316936","phase":"PHASE4","title":"Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery","status":"COMPLETED","sponsor":"Silverstein Eye Centers","startDate":"2019-12-10","conditions":"Cataract Surgery","enrollment":15},{"nctId":"NCT05099055","phase":"PHASE3","title":"Dexmedetomine as Adjuvant for Spinal Anesthesia in Elective Cesarian Sections : a Pilot Study","status":"COMPLETED","sponsor":"St. Justine's Hospital","startDate":"2022-03-15","conditions":"Analgesia, Analgesics, Opioid, Anesthesia, Obstetrical","enrollment":42},{"nctId":"NCT04829799","phase":"PHASE4","title":"Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2022-02","conditions":"Pain Reduction","enrollment":""},{"nctId":"NCT02895035","phase":"PHASE4","title":"Comparison of Epinephrine and Phenylephrine/Ketorolac With Regards to Pupil Size","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2016-09-01","conditions":"Cataract","enrollment":59},{"nctId":"NCT02093689","phase":"PHASE3","title":"Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery","status":"TERMINATED","sponsor":"Omeros Corporation","startDate":"2014-02","conditions":"Intraocular Lens Replacement, Intraoperative Floppy Iris Syndrome","enrollment":18},{"nctId":"NCT01365650","phase":"PHASE1","title":"Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of Oxymetazoline Hydrochloride and Fluticasone Propionate on the Absorption and Tolerability of Intranasal Ketorolac Tromethamine in Participants With Allergic Rhinitis","status":"COMPLETED","sponsor":"Egalet Ltd","startDate":"2007-12","conditions":"Allergic Rhinitis","enrollment":24},{"nctId":"NCT01579565","phase":"PHASE3","title":"Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification","status":"COMPLETED","sponsor":"Omeros Corporation","startDate":"2012-04","conditions":"Intraocular Lens Replacement","enrollment":416},{"nctId":"NCT01355588","phase":"PHASE1","title":"Tolerability, Safety and Pharmacokinetics of Four Formulations of Ketorolac Tromethamine in Healthy Volunteers","status":"COMPLETED","sponsor":"Egalet Ltd","startDate":"2005-08","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT01363089","phase":"PHASE1","title":"Study to Assess the PK of Ketorolac Tromethamine Intranasal and to Assess the Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine","status":"COMPLETED","sponsor":"Egalet Ltd","startDate":"2007-01","conditions":"Assess Pharmacokinetics of Ketorolac Tromethamine Intranasal and Assess Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine","enrollment":21},{"nctId":"NCT01454063","phase":"PHASE3","title":"Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification","status":"COMPLETED","sponsor":"Omeros Corporation","startDate":"2011-09","conditions":"Intraocular Lens Replacement","enrollment":405},{"nctId":"NCT01897155","phase":"PHASE4","title":"Effect of Acute Arterial Hypertension on Morphine's Requirements and Postsurgical Pain.","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2010-01","conditions":"Hypertensive Disease, Pain, Postoperative","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Omidria"],"phase":"marketed","status":"active","brandName":"Phenylephrine-ketorolac","genericName":"Phenylephrine-ketorolac","companyName":"Milton S. Hershey Medical Center","companyId":"milton-s-hershey-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Phenylephrine-ketorolac is a combination drug that uses a sympathomimetic vasoconstrictor (phenylephrine) and a nonsteroidal anti-inflammatory agent (ketorolac) to reduce bleeding and inflammation during ophthalmic surgery. Used for Intraoperative mydriasis and hemostasis during ophthalmic surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}